Pathogenesis of systemic sclerosis—current concept and emerging treatments

Masutaka Furue, Chikage Mitoma, Hiroki Mitoma, Gaku Tsuji, Takahito Chiba, Takeshi Nakahara, Uchi Hiroshi, Takafumi Kadono

研究成果: ジャーナルへの寄稿評論記事

16 引用 (Scopus)

抄録

Systemic sclerosis (SSc) is an intractable multifaceted disease with high mortality. Although its pathogenesis is not fully understood, recent studies have advanced our knowledge on SSc. The cardinal pathological features of SSc are autoimmunity, vasculopathy, and fibrosis. The B cells in SSc are constitutively activated and lead to the production of a plethora of autoantibodies, such as anti-topoisomerase I and anti-centromere antibodies. In addition to these autoantibodies, which are valuable for diagnostic criteria or biomarkers, many other autoantibodies targeting endothelial cells, including endothelin type A receptor and angiotensin II type I receptor, are known to be functional and induce activation or apoptosis of endothelial cells. The autoantibody-mediated endothelial cell perturbation facilitates inflammatory cell infiltration, cytokine production, and myofibroblastic transformation of fibroblasts and endothelial cells. Profibrotic cytokines, such as transforming growth factor β, connective tissue growth factor, interleukin 4/interleukin 13, and interleukin 6, play a pivotal role in collagen production from myofibroblasts. Specific treatments targeting these causative molecules may improve the clinical outcomes of patients with SSc. In this review, we summarize recent topics on the pathogenesis (autoantibodies, vasculopathy, and fibrosis), animal models, and emerging treatments for SSc.

元の言語英語
ページ(範囲)790-797
ページ数8
ジャーナルImmunologic Research
65
発行部数4
DOI
出版物ステータス出版済み - 8 1 2017

Fingerprint

Systemic Scleroderma
Autoantibodies
Endothelial Cells
Fibrosis
Therapeutics
Cytokines
Connective Tissue Growth Factor
Endothelin A Receptors
Angiotensin I
Type I DNA Topoisomerase
Angiotensin Receptors
Myofibroblasts
Interleukin-13
Centromere
Transforming Growth Factors
Autoimmunity
Interleukin-4
Anti-Idiotypic Antibodies
Interleukin-6
B-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology

これを引用

Pathogenesis of systemic sclerosis—current concept and emerging treatments. / Furue, Masutaka; Mitoma, Chikage; Mitoma, Hiroki; Tsuji, Gaku; Chiba, Takahito; Nakahara, Takeshi; Hiroshi, Uchi; Kadono, Takafumi.

:: Immunologic Research, 巻 65, 番号 4, 01.08.2017, p. 790-797.

研究成果: ジャーナルへの寄稿評論記事

Furue, Masutaka ; Mitoma, Chikage ; Mitoma, Hiroki ; Tsuji, Gaku ; Chiba, Takahito ; Nakahara, Takeshi ; Hiroshi, Uchi ; Kadono, Takafumi. / Pathogenesis of systemic sclerosis—current concept and emerging treatments. :: Immunologic Research. 2017 ; 巻 65, 番号 4. pp. 790-797.
@article{c5069ec7d6a046ce9d7a1991584e2a75,
title = "Pathogenesis of systemic sclerosis—current concept and emerging treatments",
abstract = "Systemic sclerosis (SSc) is an intractable multifaceted disease with high mortality. Although its pathogenesis is not fully understood, recent studies have advanced our knowledge on SSc. The cardinal pathological features of SSc are autoimmunity, vasculopathy, and fibrosis. The B cells in SSc are constitutively activated and lead to the production of a plethora of autoantibodies, such as anti-topoisomerase I and anti-centromere antibodies. In addition to these autoantibodies, which are valuable for diagnostic criteria or biomarkers, many other autoantibodies targeting endothelial cells, including endothelin type A receptor and angiotensin II type I receptor, are known to be functional and induce activation or apoptosis of endothelial cells. The autoantibody-mediated endothelial cell perturbation facilitates inflammatory cell infiltration, cytokine production, and myofibroblastic transformation of fibroblasts and endothelial cells. Profibrotic cytokines, such as transforming growth factor β, connective tissue growth factor, interleukin 4/interleukin 13, and interleukin 6, play a pivotal role in collagen production from myofibroblasts. Specific treatments targeting these causative molecules may improve the clinical outcomes of patients with SSc. In this review, we summarize recent topics on the pathogenesis (autoantibodies, vasculopathy, and fibrosis), animal models, and emerging treatments for SSc.",
author = "Masutaka Furue and Chikage Mitoma and Hiroki Mitoma and Gaku Tsuji and Takahito Chiba and Takeshi Nakahara and Uchi Hiroshi and Takafumi Kadono",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s12026-017-8926-y",
language = "English",
volume = "65",
pages = "790--797",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Pathogenesis of systemic sclerosis—current concept and emerging treatments

AU - Furue, Masutaka

AU - Mitoma, Chikage

AU - Mitoma, Hiroki

AU - Tsuji, Gaku

AU - Chiba, Takahito

AU - Nakahara, Takeshi

AU - Hiroshi, Uchi

AU - Kadono, Takafumi

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Systemic sclerosis (SSc) is an intractable multifaceted disease with high mortality. Although its pathogenesis is not fully understood, recent studies have advanced our knowledge on SSc. The cardinal pathological features of SSc are autoimmunity, vasculopathy, and fibrosis. The B cells in SSc are constitutively activated and lead to the production of a plethora of autoantibodies, such as anti-topoisomerase I and anti-centromere antibodies. In addition to these autoantibodies, which are valuable for diagnostic criteria or biomarkers, many other autoantibodies targeting endothelial cells, including endothelin type A receptor and angiotensin II type I receptor, are known to be functional and induce activation or apoptosis of endothelial cells. The autoantibody-mediated endothelial cell perturbation facilitates inflammatory cell infiltration, cytokine production, and myofibroblastic transformation of fibroblasts and endothelial cells. Profibrotic cytokines, such as transforming growth factor β, connective tissue growth factor, interleukin 4/interleukin 13, and interleukin 6, play a pivotal role in collagen production from myofibroblasts. Specific treatments targeting these causative molecules may improve the clinical outcomes of patients with SSc. In this review, we summarize recent topics on the pathogenesis (autoantibodies, vasculopathy, and fibrosis), animal models, and emerging treatments for SSc.

AB - Systemic sclerosis (SSc) is an intractable multifaceted disease with high mortality. Although its pathogenesis is not fully understood, recent studies have advanced our knowledge on SSc. The cardinal pathological features of SSc are autoimmunity, vasculopathy, and fibrosis. The B cells in SSc are constitutively activated and lead to the production of a plethora of autoantibodies, such as anti-topoisomerase I and anti-centromere antibodies. In addition to these autoantibodies, which are valuable for diagnostic criteria or biomarkers, many other autoantibodies targeting endothelial cells, including endothelin type A receptor and angiotensin II type I receptor, are known to be functional and induce activation or apoptosis of endothelial cells. The autoantibody-mediated endothelial cell perturbation facilitates inflammatory cell infiltration, cytokine production, and myofibroblastic transformation of fibroblasts and endothelial cells. Profibrotic cytokines, such as transforming growth factor β, connective tissue growth factor, interleukin 4/interleukin 13, and interleukin 6, play a pivotal role in collagen production from myofibroblasts. Specific treatments targeting these causative molecules may improve the clinical outcomes of patients with SSc. In this review, we summarize recent topics on the pathogenesis (autoantibodies, vasculopathy, and fibrosis), animal models, and emerging treatments for SSc.

UR - http://www.scopus.com/inward/record.url?scp=85019155456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019155456&partnerID=8YFLogxK

U2 - 10.1007/s12026-017-8926-y

DO - 10.1007/s12026-017-8926-y

M3 - Review article

C2 - 28488090

AN - SCOPUS:85019155456

VL - 65

SP - 790

EP - 797

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 4

ER -